Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 19, 2020

View Archived Issues

'Superkiller' is broad-spectrum antiviral target

CDK4/6 inhibitors affect transcriptional landscape

PTC Therapeutics initiates phase I study of PTC-518

Intermittent schedule of CH-5126766 shows activity across several RAS-RAF-driven cancers

Peptide-conjugated ReNcell-derived EVs: a new therapeutic approach for pulmonary hypertension

Phase I data presented for AMG-890 in patients with elevated plasma Lp(a)

Neuro-drug repurposed to treat MDR Gram-negative sepsis

Pionyr initiates phase I study of its immuno-oncology candidate, PY-314

Phase II/III CAPELLA study of lenacapavir meets primary endpoint

First-in-human biomarker analysis for JNJ-55920839 in SLE

University of Kansas, Fox Chase Cancer Center describe anti-CTLA-4 antibodies

Yeda Research & Development patents polypeptides comprising propeptides of human lysyl oxidase

PROTACs targeting CDK12 and/or a CDK9 synthesized at the Dana-Farber Cancer Institute

JAK inhibitor prodrugs discovered at Theravance Biopharma

Beta Pharma identifies new HCV NS5A inhibitors

Supemtek quadrivalent recombinant influenza vaccine approved in E.U.

Preliminary phase I data for the half-life extended BiTE immune therapy, AMG-757

Bioventus receives IND clearance to study PTP-001 for knee osteoarthritis

FDA clears initiation of phase I trial of anti-LILRB2/ILT4 antibody JTX-8064

Synergy seen for DA-1241 with DPP4 inhibitor for the treatment of NASH

BioVersys initiates phase I testing of BV-100 for carbapenem-resistant A. baumannii infections

Interim data from phase Ib/IIa study of VBI-2601 for chronic hepatitis B

Genoscience completes phase Ib study of GNS-561 in primary and secondary liver cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...